Multifunctional receptor-targeting antibodies for cancer therapy

The Lancet Oncology

Volumn 16, Issue 15, 2015, Pages e543-e554

  Zhu, Yanni ^a   Choi, Sung Hugh ^a   Shah, Khalid ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BAY 2020112; BISPECIFIC ANTIBODY; BLINATUMOMAB; CD20BI ANTIBODY; CELL SURFACE RECEPTOR; CETUXIMAB; DT 2219ARL; DULIGOTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERTUMAXOMAB; F6 734; FBTA 05; LAPATINIB; LY 3164530; MDX 447; MGD 006; MGD 007; MM 111; NANOBODY; ONARTUZUMAB; PROTEIN TYROSINE KINASE; R 1507; RM28 ANTIBODY; RO 6958688; SOLITOMAB; TF2 ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; B CELL LYMPHOMA; BREAST CANCER; CANCER THERAPY; CELL MEDIATED CYTOTOXICITY; COLORECTAL CANCER; COLORECTAL CARCINOMA; DRUG CONJUGATION; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; IMMUNOCOMPETENT CELL; LEUKEMIA; MACROPHAGE; METASTASIS; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID TUMOR; THYROID MEDULLARY CARCINOMA; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS;

ANTIBODIES; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTORS, CELL SURFACE;

EID: 84960957473     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00039-X     Document Type: Review

References (117)

1. Hudis CA Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007, 357:39-51.
2. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90:2188-2195.
3. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
4. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013, 13:714-726.
5. Quail DF, Joyce JA Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013, 19:1423-1437.
6. van de Water JA, Bagci-Onder T, Agarwal AS, et al. Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. Proc Natl Acad Sci USA 2012, 109:16642-16647.
7. Maussang D, Mujic-Delic A, Descamps FJ, et al. Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo. J Biol Chem 2013, 288:29562-29572.
8. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature 1993, 363:446-448.
9. Chapman AP, Antoniw P, Spitali M, West S, Stephens S, King DJ Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 1999, 17:780-783.
10. Harmsen MM, De Haard HJ Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol 2007, 77:13-22.
11. Holmes D Buy buy bispecific antibodies. Nat Rev Drug Discov 2011, 10:798-800.
12. Coloma MJ, Morrison SL Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol 1997, 15:159-163.
13. Weidle UH, Tiefenthaler G, Weiss EH, Georges G, Brinkmann U The intriguing options of multispecific antibody formats for treatment of cancer. Cancer Genomics Proteomics 2013, 10:1-18.
14. Bostrom J, Yu SF, Kan D, et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009, 323:1610-1614.
15. Sun C, Bernards R Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. Trends Biochem Sci 2014, 39:465-474.
16. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726.
17. Nahta R, Esteva FJ HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006, 8:215.
18. Dienstmann R, De Dosso S, Felip E, Tabernero J Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. Mol Oncol 2012, 6:15-26.
19. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
20. Wang S, Chen C, Meng Y, et al. Effective suppression of breast tumor growth by an anti-EGFR/ErbB2 bispecific antibody. Cancer Lett 2012, 325:214-219.
21. Schaefer G, Haber L, Crocker LM, et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011, 20:472-486.
22. Hojjat-Farsangi M Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies. Int J Mol Sci 2014, 15:13768-13801.
23. Graus-Porta D, Beerli RR, Daly JM, Hynes NE ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997, 16:1647-1655.
24. Hirsch FR, Varella-Garcia M, Cappuzzo F Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 2009, 28(suppl 1):S32-S37.
25. Tsutsui S, Ohno S, Murakami S, Kataoka A, Kinoshita J, Hachitanda Y Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer. Surgery 2003, 133:219-221.
26. Engelman JA, Janne PA, Mermel C, et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 2005, 102:3788-3793.
27. Buck E, Eyzaguirre A, Haley JD, Gibson NW, Cagnoni P, Iwata KK Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Mol Cancer Ther 2006, 5:2051-2059.
28. Lee-Hoeflich ST, Crocker L, Yao E, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008, 68:5878-5887.
29. Fitzpatrick VD, Pisacane PI, Vandlen RL, Sliwkowski MX Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4. FEBS Lett 1998, 431:102-106.
30. Sergina NV, Rausch M, Wang D, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445:437-441.
31. McDonagh CF, Huhalov A, Harms BD, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther 2012, 11:582-593.
32. Buck E, Eyzaguirre A, Rosenfeld-Franklin M, et al. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 2008, 68:8322-8332.
33. Guix M, Faber AC, Wang SE, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008, 118:2609-2619.
34. Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 2006, 66:10100-10111.
35. Kaulfuss S, Burfeind P, Gaedcke J, Scharf JG Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis. Mol Cancer Ther 2009, 8:821-833.
36. Dong J, Sereno A, Aivazian D, et al. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. MAbs 2011, 3:273-288.
37. Croasdale R, Wartha K, Schanzer JM, et al. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition. Arch Biochem Biophys 2012, 526:206-218.
38. Ramalingam SS, Spigel DR, Chen D, et al. Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol 2011, 29:4574-4580.
39. Castoldi R, Ecker V, Wiehle L, et al. A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity. Oncogene 2013, 32:5593-5601.
40. Prat M, Crepaldi T, Pennacchietti S, Bussolino F, Comoglio PM Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci 1998, 111(pt 2):237-247.
41. Merchant M, Ma X, Maun HR, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci USA 2013, 110:E2987-E2996.
42. Martens T, Schmidt NO, Eckerich C, et al. A novel one-armed anti c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006, 12:6144-6152.
43. Jin H, Yang R, Zheng Z, et al. MetMAb, the one-armed 5D5 anti c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008, 68:4360-4368.
44. Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2013, 31:4105-4114.
45. Hu S, Fu W, Xu W, et al. Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. Cancer Res 2015, 75:159-170.
46. Anderl J, Faulstich H, Hechler T, Kulke M Antibody-drug conjugate payloads. Methods Mol Biol 2013, 1045:51-70.
47. Sharkey RM, Rossi EA, McBride WJ, Chang CH, Goldenberg DM Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin Nucl Med 2010, 40:190-203.
48. Saleh MN, Sugarman S, Murray J, et al. Phase I trial of the anti Lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithelial tumors. J Clin Oncol 2000, 18:2282-2292.
49. Tolcher AW BR96-doxorubicin: been there, done that!. J Clin Oncol 2000, 18:4000.
50. Tolcher AW, Sugarman S, Gelmon KA, et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol 1999, 17:478-484.
51. Apelgren LD, Zimmerman DL, Briggs SL, Bumol TF Antitumor activity of the monoclonal antibody-Vinca alkaloid immunoconjugate LY203725 (KS1/4-4-desacetylvinblastine-3-carboxhydrazide) in a nude mouse model of human ovarian cancer. Cancer Res 1990, 50:3540-3544.
52. Laguzza BC, Nichols CL, Briggs SL, et al. New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activity. J Med Chem 1989, 32:548-555.
53. Petersen BH, DeHerdt SV, Schneck DW, Bumol TF The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies. Cancer Res 1991, 51:2286-2290.
54. Kulkarni PN, Blair AH, Ghose T, Mammen M Conjugation of methotrexate to IgG antibodies and their F(ab)2 fragments and the effect of conjugated methotrexate on tumor growth in vivo. Cancer Immunol Immunother 1985, 19:211-214.
55. Uadia P, Blair AH, Ghose T Tumor and tissue distribution of a methotrexate-anti-EL4 immunoglobulin conjugate in EL4 lymphoma-bearing mice. Cancer Res 1984, 44:4263-4266.
56. LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 2011, 17:6437-6447.
57. Gupta M, Lorusso PM, Wang B, et al. Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Pharmacol 2012, 52:691-703.
58. Senter PD, Sievers EL The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012, 30:631-637.
59. Ricart AD Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 2011, 17:6417-6427.
60. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008, 26:5156-5164.
61. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005, 352:441-449.
62. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012, 30:2183-2189.
63. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012, 367:1783-1791.
64. Roovers RC, Vosjan MJ, Laeremans T, et al. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Int J Cancer 2011, 129:2013-2024.
65. Vosjan MJ, Vercammen J, Kolkman JA, Stigter-van Walsum M, Revets H, van Dongen GA Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy. Mol Cancer Ther 2012, 11:1017-1025.
66. Oliveira S, Heukers R, Sornkom J, Kok RJ, van Bergen En Henegouwen PM Targeting tumors with nanobodies for cancer imaging and therapy. J Control Release 2013, 172:607-617.
67. Coppieters K, Dreier T, Silence K, et al. Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum 2006, 54:1856-1866.
68. Harmsen MM, van Solt CB, Fijten HP, et al. Passive immunization of guinea pigs with llama single-domain antibody fragments against foot-and-mouth disease. Vet Microbiol 2007, 120:193-206.
69. Hmila I, Abdallah RB, Saerens D, et al. VHH, bivalent domains and chimeric Heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin AahI'. Mol Immunol 2008, 45:3847-3856.
70. Stuckey DW, Hingtgen SD, Karakas N, Rich BE, Shah K Engineering toxin-resistant therapeutic stem cells to treat brain tumors. Stem Cells 2014, 33:589-600.
71. Pardoll DM The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12:252-264.
72. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
73. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
74. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015, 372:311-319.
75. Kim JW, Eder JP Prospects for targeting PD-1 and PD-L1 in various tumor types. Oncology (Williston Park) 2014, 28(suppl 3):15-28.
76. Liao D, Johnson RS Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 2007, 26:281-290.
77. Gillies RJ, Robey I, Gatenby RA Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 2008, 49(suppl 2):24S-42S.
78. Yokoi K, Thaker PH, Yazici S, et al. Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res 2005, 65:3716-3725.
79. Amin DN, Hida K, Bielenberg DR, Klagsbrun M Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res 2006, 66:2173-2180.
80. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004, 18:338-340.
81. Mabry R, Gilbertson DG, Frank A, et al. A dual-targeting PDGFRbeta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo. MAbs 2010, 2:20-34.
82. Kienast Y, Klein C, Scheuer W, et al. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin Cancer Res 2013, 19:6730-6740.
83. Wilson NS, Yang A, Yang B, et al. Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth. Cancer Cell 2012, 22:80-90.
84. Burges A, Wimberger P, Kumper C, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res 2007, 13:3899-3905.
85. Gupta P, Goldenberg DM, Rossi EA, Chang CH Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias. Blood 2010, 116:3258-3267.
86. Hoffmann P, Hofmeister R, Brischwein K, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 2005, 115:98-104.
87. Korn T, Nettelbeck DM, Volkel T, Muller R, Kontermann RE Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv. J Gene Med 2004, 6:642-651.
88. Kellner C, Bruenke J, Stieglmaier J, et al. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. J Immunother 2008, 31:871-884.
89. Otz T, Grosse-Hovest L, Hofmann M, Rammensee HG, Jung G A bispecific single-chain antibody that mediates target cell-restricted, supra-agonistic CD28 stimulation and killing of lymphoma cells. Leukemia 2009, 23:71-77.
90. Herrmann T, Grosse-Hovest L, Otz T, Krammer PH, Rammensee HG, Jung G Construction of optimized bispecific antibodies for selective activation of the death receptor CD95. Cancer Res 2008, 68:1221-1227.
91. Michaelson JS, Demarest SJ, Miller B, et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. MAbs 2009, 1:128-141.
92. Loffler A, Kufer P, Lutterbuse R, et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000, 95:2098-2103.
93. Topp MS, Gokbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2015, 16:57-66.
94. Rosenberg SA, Yang JC, White DE, Steinberg SM Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998, 228:307-319.
95. Cohen J IL-12 deaths: explanation and a puzzle. Science 1995, 270:908.
96. Becker JC, Pancook JD, Gillies SD, Mendelsohn J, Reisfeld RA Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc Natl Acad Sci USA 1996, 93:2702-2707.
97. Xiang R, Lode HN, Dolman CS, et al. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res 1997, 57:4948-4955.
98. Muller D Antibody-cytokine fusion proteins for cancer immunotherapy: an update on recent developments. BioDrugs 2014, 28:123-131.
99. Dela Cruz JS, Morrison SL, Penichet ML Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein. Vaccine 2005, 23:4793-4803.
100. Lode HN, Xiang R, Dreier T, Varki NM, Gillies SD, Reisfeld RA Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 1998, 91:1706-1715.
101. Becker JC, Pancook JD, Gillies SD, Furukawa K, Reisfeld RA T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med 1996, 183:2361-2366.
102. Mantovani A, Sica A Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010, 22:231-237.
103. Jinushi M, Chiba S, Yoshiyama H, et al. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci USA 2011, 108:12425-12430.
104. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010, 362:875-885.
105. Chen J, Yao Y, Gong C, et al. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 2011, 19:541-555.
106. Pander J, Heusinkveld M, van der Straaten T, et al. Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin Cancer Res 2011, 17:5668-5673.
107. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009, 360:563-572.
108. De Palma M, Lewis CE Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013, 23:277-286.
109. Tsagozis P, Eriksson F, Pisa P Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages. Cancer Immunol Immunother 2008, 57:1451-1459.
110. Qian BZ, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475:222-225.
111. Germano G, Frapolli R, Simone M, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 2010, 70:2235-2244.
112. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 2005, 65:3437-3446.
113. Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1666.
114. Ries CH, Cannarile MA, Hoves S, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 2014, 25:846-859.
115. Cassier PA, Italiano A, Gomez-Roca CA, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol 2015, 16:949-956.
116. Cieslewicz M, Tang J, Yu JL, et al. Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival. Proc Natl Acad Sci USA 2013, 110:15919-15924.
117. Yao YD, Sun TM, Huang SY, et al. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. Sci Transl Med 2012, 4:130ra48.